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ABSTRACT 
 
DNA methylation is a well-known biomarker of aging. Many previous studies have reported 
the change of DNA methylation patterns with age, and analyzed DNA methylation in 
association with aging outcomes. However, most publications were based on cross-sectional 
data while longitudinal evidence was largely missing. Hence, in this thesis, we used 
longitudinal measures of DNA methylation from the Swedish Adoption/Twin Study of Aging 
(SATSA) to comprehensively study the role of DNA methylation in aging.  
The first three studies in this thesis focus on different mechanisms of DNA methylation 
related to aging, including methylation level, methylation variability and epigenetic mutation. 
In Study I, we investigated the longitudinal change of methylation level with age from an 
epigenome-wide association study (EWAS) using a mixed effect model. We identified 1316 
age-related CpGs and successfully validated them in two external cohorts. Further, we 
analyzed the methylation difference between paired twins at the same time-point, and found it 
increased with age. We also identified genetic effect on age-associated CpGs, but the effect 
was independent on age. 
In Study II, we first developed a method that could properly model the longitudinal change of 
methylation variability with age in simulated data. The method included a linear model to 
regress methylation on age, followed by a random intercept model to regress the absolute 
residuals on age. Next, we applied the method in an EWAS and identified 570 age-varying 
CpGs. The inter-individual variance of most CpGs increased with age longitudinally. 
In Study III, we comprehensively studied epigenetic mutations, which are extreme outliers in 
the distribution of methylation level. The number of epigenetic mutations significantly 
increased with age in our longitudinal data. We also identified other factors associated with 
epigenetic mutations, including sex, B cell, sample quality, cancer diagnosis and first genetic 
principal component. Further, we classified CpGs into frequent mutated CpGs, highly 
methylated outliers (HMO) and lowly methylated outliers (LMO), and found frequent HMOs 
were more related to biological factors. In the end, we validated epigenetic mutations using 
bisulfite pyrosequencing and proved that epigenetic mutations were persist and could 
accumulate in aging. 
In Study IV, we performed an EWAS to analyze methylation levels, methylation variability 
and epigenetic mutations in association with mortality. We observed age-varying effect of 
methylation level on all-cause mortality which may explain the poor replication in previous 
studies. We also identified CpGs of cancer genes related to death from cancer. In the end, we 
provided evidence that methylation variability could predict all-cause mortality.  
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1 INTRODUCTION  
1.1 EPIGENETICS AND DNA METHYLATION 
1.1.1 Epigenetics  
Epigenetics is a study of changes in gene functions that are heritable between cell generations 
without alterations in DNA sequence [1]. The term epigenetic was first introduced by Conrad 
Waddington [2], and is now widely used to describe all regulated processes from genetic 
material to the final product [3]. The definition of epigenetic covers a number of mechanisms 
in molecular biology. The widely-studied epigenetic mechanisms include DNA methylation, 
histone modification, non-coding RNA and so on. Both DNA methylation and histone 
modification organize chromatin structure, which determines the accessibility of the DNA 
sequence to transcription factors and therefore controls gene expression. The X chromosome 
inactivation in women is a typical example of an epigenetic regulation, where the additional 
X chromosome DNA is heavily packed in condensed heterochromatin for dosage 
compensation [4]. In addition, microRNAs are involved in RNA silencing and post-
transcriptional regulation of gene expression [5]. All these epigenetic markers cooperate with 
each other and together present an epigenetic pattern that regulates gene expression and thus 
determines cell function. The distinct epigenetic patterns between different cell types create 
an epigenetic barrier which is the key to maintain cell identify. The epigenetic pattern is also 
inherited between cell generations so that the cell function is maintained after cell division.  
Unlike DNA sequence, which does not change except somatic mutations, epigenetic markers 
can be modified due to various environmental exposures in human life time. How epigenetic 
markers change with different factors and further influence gene expression is the main 
research question in the field. 
1.1.2 DNA methylation  
DNA methylation is an epigenetic mechanism where methyl groups can be added to the DNA 
sequence with covalent bonds. DNA methylation mostly occurs on a cytosine followed by a 
guanine (CpG), where a methyl group is added to the 5’ end of the cytosine to produce 5-
methylcytosine (5-mC). There are other types of chemical modifications on cytosine, such as 
DNA hydroxymethylation (5-hmC), but methylation is the most common modification [6]. 
There are over 28 million CpG sites in the human genome and they are not evenly distributed. 
CpG-rich regions are named CpG islands which are about 300 to 3000 base pairs (bps) in 
length [7]. CpG islands have been found in about 70% of gene promoter regions located close 
to transcription start sites, and hence regulate gene expression [8]. However, about half of the 
CpG islands found in humans are located in gene bodies or intergenic regions [9].  
The reaction of adding a methyl group to an unmethylated CpG can be catalyzed by three 
different DNA methyltransferases (DNMTs): DNMT1, DNMT3a and DNMT3b. DNMT1, 
which is also called the methylation maintainer, keeps DNA methylation pattern unchanged 
during cell replication by targeting hemi-methylated CpGs on the newly synthesized DNA 
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strand [10]. Therefore, DNA methylation can be inherited between cell generations allowing 
cells to maintain their cellular functions. The other two enzymes, DNMT3a and DNMT3b, 
are responsible for de novo DNA methylation [11], which is essential to establish DNA 
methylation pattern in embryonic development and cell differentiation [12,13]. On the other 
hand, the process of demethylation can be classified into passive and active processes [14]. 
The passive process refers to the dilution of 5mC in replication, where DNMT1 fails to 
maintain the methylation status so the cell-average methylation level decreases with 
replication rounds. The active demethylation process includes several steps of oxidation 
reactions catalyzed by ten-eleven translocation (TET) family enzymes, and followed by either 
passive replication dilution or base excision and repair processes (Figure 1). 
 
Figure 1. The pathway of DNA methylation and demethylation. The figure is modified from 
Kohli et al [14] with permission from Springer Nature. 
DNA methylation is one of the most important epigenetic processes involved in regulating 
gene expression. The methylation status of different gene regulatory regions can regulate 
gene expression through different mechanisms. In promoter regions, DNA methylation can 
change the availability of gene promoters to transcription factors. In detail, methylated DNA 
can either inhibit the binding of transcription factors or recruit protein complexes that 
catalyze histone deacetylation, which results in a condensed chromatin and silencing of gene 
expression [15]. DNA methylation in enhancer regions can also reduce gene expression 
through similar mechanisms [16], and some evidences suggest enhancer methylation better 
correlates with gene expression than promoter methylation [17]. On the other hand, DNA 
methylation in gene body has bell-shaped correlation with gene expression, where both 
highly and lowly expressed genes have low levels of methylation in gene bodies [18].  
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DNA methylation patterns are different between cell types as they are part of the epigenetic 
barrier that preserve somatic cell identity [19]. Thus, it becomes an issue in association 
studies to distinguish true biological signals from what is caused by cellular heterogeneity 
[20]. As cellular compositions are not always measured in mixed cell samples, many 
algorithms has been developed to use highly cell-specific CpGs to predict cellular 
compositions. Typically, for whole blood samples, the Houseman method has been used to 
estimate compositions of leukocyte subtypes in combination with an external reference of 
purified leukocyte samples [21]. Alternatively, emerging reference-free methods have been 
developed to improve estimates of cellular compositions and remove the effect of cellular 
heterogeneity from methylation data [22]. 
The variance of DNA methylation levels across individuals is usually larger in CpGs of 
intermediate methylation levels, whereas CpGs of either high or low methylation levels show 
high consistency between and within individuals. The inter-individual variance of DNA 
methylation can be explained by genetic [23], environmental [24] and stochastic effects [25]. 
Growing evidence suggest that DNA methylation can mediate the genetic and environmental 
effects on complex diseases [26].  
Studies on twins revealed that the monozygotic (MZ) twins have a higher correlation of DNA 
methylation than dizygotic (DZ) twins. The methylation heritability is estimated between 5% 
to 19% across the genome in different tissues [27–30]. CpGs with high heritability (h2≥0.5) 
usually have intermediate methylation levels and large variance across individuals [31]. To 
further analyze the genetic effect on methylation, studies on methylation quantitative trait loci 
(meQTL) have identified CpGs associated with single nucleotide polymorphisms (SNP) 
[23,32]. In general, the association become stronger when CpGs are located closer to their 
associated SNPs on the DNA sequence (cis-meQTLs). However, distal associations (trans-
meQTLs) were also identified even between different chromosomes [33].   
1.1.3 DNA methylation array  
The Infinium Human Methylation 450K BeadChip, 450k array in short, is a microarray 
developed by Illumina, Inc. to perform a whole genome screening of DNA methylation levels 
in human. As suggested by the name, the 450k array is capable of measuring over 450 
thousands CpGs. It is an extension of the predecessor 27k array. Recently, the 450k array 
started to be replaced by the EPIC array which can measure more than 850 thousands CpGs. 
One 450k array plate consists of 8 slides and each slide has 12 wells, so that in total 96 
samples can be tested in a plate at a time.  
To measure DNA methylation, a bisulfite reaction is first required to convert unmethylated 
cytosine to uracil, leaving methylated cytosine unchanged. Then, after polymerase chain 
reaction, unmethylated C-G pairs were turned into T-A pairs. Next, the 450k array can detect 
the C/T signals at specific CpG loci and therefore measure methylation levels. Specifically, 
there are two types of probes in the 450k array adopting different mechanisms to measure the 
signal. A type I probe has a pair of beads to detect methylated and unmethylated CpGs 
 4 
respectively using the allele-specific oligonucleotides approach [34]. On the other hand, a 
type II probe only have one bead to detect both methylation status using the single-base 
extension approach [35]. Both types of probes produce fluorescent signals that represent 
methylated and unmethylated status. The two signals can be then calculated into beta-value, 
which is a variable between 0 and 1 representing the proportion of methylated CpGs in the 
study sample. The beta-value can be further transformed into M-value through a logit2-
transformation. Beta-value is easier to interpret while M-value may perform better in 
statistical analysis [36]. 
 
Figure 2. The mechanisms to measure DNA methylation in the 450k array including A) Type 
I probe and B) Type II probe. The figure is reprinted from Bibikova et al. [37] with 
permission from Elsevier. 
The 450k array was designed to cover CpGs located in different regions of 99% Refseq genes 
[38]. However, since the human genome has over 28 million CpGs, only less than 2% of the 
whole methylome was measured by the 450k array. Thus, results of studies using 450k array 
are based on a small selection of human CpGs. 
In terms of measure quality, Illumina claimed an over 98% reproducibility between technical 
replicates. But studies reported some probes of low intra-class correlation between replicates 
[39]. These CpGs mostly have low variance across samples, so they are more influenced by 
measurement errors. Also, low-variance CpGs are less likely to present biological signals 
from statistical analysis, so some studies simply removed them before the analysis. 
1.1.4 Epigenome-wide association study (EWAS) 
Epigenome-wide association study (EWAS) is a hypothesis-free design to exam the effect of 
DNA methylation on a complex trait, aiming to identify CpGs significantly associated with 
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the trait from the methylome. The idea of EWAS is similar to the genome-wide association 
study (GWAS), as they both applied the same statistical model on all measured SNPs or 
CpGs to test their associations with a trait [40].  
Based on different measurement platforms, the total number of tests in an EWAS may vary 
from three to eight hundred thousand. Thus, the multiple testing problem needs to be 
considered in order to reduce false positive findings. In GWAS, a standard threshold was 
determined by the number of common independent variants in human genome [41]. However, 
there is no consensus on the number of independent tests in EWAS because of long-range 
correlations of DNA methylation between distal regulatory sites [42]. Most EWAS 
publications used the Bonferroni correction or the false discovery rate (FDR) [43] to 
determine a significance threshold. Also, as DNA methylation is more dynamic than DNA 
sequence, confounding environmental factors need to be adjusted in the EWAS model [40]. 
Moreover, repeated measures of DNA methylation can help estimate the individual trajectory 
over time, and can model the effect of exposures on the individual difference in the 
longitudinal change of DNA methylation. 
1.2 DNA METHYLATION IN RELATION TO AGING  
1.2.1 Molecular biology of aging  
Aging is the process of losing physical and mental abilities with time, which ultimately leads 
to death [44]. It is the major risk factor for chronic diseases, such as cancer, dementia, 
diabetes, cardiovascular diseases (CVD) and autoimmune disorders [45]. To determine 
molecular bases of aging, studies have focused on lifespan-related gene mutations and 
functional decline in cell, tissue, organ and system levels [46]. At the cellular level, several 
mechanisms related to aging have been reported, including telomere shortening [47], declined 
genome maintenance [48], changes in epigenetic regulation [49], loss of protein homeostasis 
[50], deregulated nutrient sensing [51] and mitochondrial dysfunction [52]. These 
mechanisms together promote the time-dependent accumulation of cellular damage, which 
can lead to either cellular senescence [53] or uncontrolled cellular overgrowth [54]. The 
accumulation of senescent cells in aged tissue is associated with organismal aging [55], and 
unregulated cell division and increased cell heterogeneity are causes of cancer [56].  
1.2.2 Age-related changes in DNA methylation 
In the first three studies of this thesis, we studied the age-related alterations in DNA 
methylation including the change of methylation levels shared by individuals, which refers to 
age-related differentially methylated regions (aDMRs) [28]; the increasing divergence in 
methylation patterns with age, which is commonly called the “epigenetic drift” [25]; and the 
accumulation of methylation outliers, which is termed “epigenetic mutation” [57] (Figure 3). 
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Figure 3. Schematic diagram shows the three types of alterations of DNA methylation related 
to aging. Each line represents the longitudinal change of DNA methylation in an individual. 
A) In age-associated CpGs, the average methylation levels change with age. B) Age-varying 
CpGs have methylation variability increase with age. C) Epigenetic mutations represent the 
development of methylation outliers with age. 
Many studies have demonstrated that DNA methylation gradually change with chronological 
age throughout the human lifetime [58,59]. In general, the global DNA methylation level 
decreases with age (hypomethylation) [60], while the DNA methylation levels in CpG islands 
increase with age (hypermethylation) [61]. Both directions of age-related change of 
methylation are associated with the aging process. Age-related hypomethylation occurs in all 
genome regions [62], especially in regulatory protein binding sites [63], and contributes to 
genomic instability and cancer initiation [64]. In CpG islands, which usually harbor gene 
promoter regions and have low methylation levels, the age-related increase in methylation 
leads to inappropriate down-regulation of genes. For example, the promoter 
hypermethylations of tumor suppressor genes highly correlate with cancer risks [65].  
Many publications of EWAS on age have identified large numbers of CpGs associated with 
chronological age using cross-sectional data [28,66–69]. Those results confirmed the global 
hypomethylations and specific hypermethylations in CpG islands. Overall, about 30% of 
CpGs measured by the 450k array showed strong or weak associations with age [31,68]. The 
strongest age-associated signal was found in the promoter region of the gene ELOVL2, where 
the DNA methylation level progressively increased during the whole lifespan [70]. However, 
the longitudinal evidence of individual change of methylation levels with age is very limited. 
1.2.3 Epigenetic clock (DNA methylation age) 
As a biomarker of aging, DNA methylation can be used to predict biological age, which is 
called epigenetic clock or DNA methylation age (DNAmAge). The predictor was usually 
built by first using a machine learning method to select informative CpGs related to age, and 
then using an a corresponding algorithm to incorporate them into an age estimate [71]. 
Among different types of biological age predictor, epigenetic clock based on DNA 
methylation is the most promising one in predicting health outcomes independent of 
chronological age [72].  
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The first two epigenetic clocks were developed by Horvath [73] and Hannum [66]. They both 
have high correlations with age, and the difference between the predicted DNAmAge and the 
chronological age can reflect the individual aging speed. Studies demonstrated that 
DNAmAge could predict all-cause mortality independent of other risk factors [74,75]. Also, 
increased DNAmAge was found associated with cancer incidence and mortality, but was less 
powerful to predict cardiovascular mortality, even though DNAmAge was predicted from 
blood samples [76]. Further age-related phenotypes and diseases were found to be associated 
with DNAmAge, include physical and cognitive fitness [77], frailty index [78], metabolic 
syndrome [79], Alzheimer’s disease [80] and Parkinson’s disease [81]. Till now, a few 
epigenetic clocks have been developed based on different tissues, algorithms and application 
purposes [82–84]. 
1.2.4 Methylation variability (Epigenetic drift) 
Epigenetic drift describes the increasing divergence in DNA methylation between individuals. 
It can be caused by the deregulation of maintaining the normal methylation pattern and the 
accumulated effect of different environmental exposures over the human life course. 
Epigenetic drift is also a hallmark of aging [45] as it may explain the difference in individual 
aging rate [66].  
Previous studies have observed epigenetic drift in aging from different perspective. Twin 
studies showed methylation differences between MZ twins increased with age [85,86]. Also, 
methylation variability, which was estimated by a test of heteroscedasticity, was reported to 
increase with age and age-related variably methylated positions (VMPs) were identified  
[66,87]. Moreover, epigenetic drift may plays an important role in aging related diseases, 
such as cancer [88,89]. However, there is a need to for longitudinal studies to follow the 
increase in methylation variability with age in the same people. Also, the study of 
methylation variability in relation to mortality is missing. 
1.2.5 Epigenetic mutation (Methylation outlier) 
Epigenetic mutation, which is known as aberrant methylation levels that could lead to 
unusual gene expression [90], is involved in cancer development and can also be an 
important factor in human aging. Unlike age-associated changes in methylation that are 
shared between individuals, epigenetic mutation is individual specific and the population 
average mostly stay unchanged. Epigenetic mutation also contributes to the increase in 
methylation divergence with age, but it is different to the methylation variability because 
epigenetic mutation focuses on rare outliers in random CpGs of conserved methylation levels. 
The accumulation of epigenetic mutations can lead to abnormal gene expression, genome 
instability, and cancer development in the aging process.  
A previous study identified methylation outliers from samples and found that the total 
number of CpG sites with aberrant methylation levels increased exponentially with age [57]. 
A later study found significantly more epigenetic mutations in hepatocellular carcinoma 
tumors than in peritumoral samples, which suggests the importance of epigenetic mutations 
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in tumorigenesis [91]. However, longitudinal studies can better demonstrate if epigenetic 
mutations are persist over time and accumulate in the aging process. 
1.2.6 Mortality  
Being the final outcome of aging, mortality could also be predicted by DNA methylation. 
Emerging studies investigated DNA methylation in association with all-cause mortality, and 
built prediction models. The first EWAS reported 58 CpGs that could predict all-cause 
mortality independent of age, sex and smoking [52]. The identified CpGs were found in 
genes involved in various diseases including diabetes, CVD, various cancers and 
neuropsychiatric disorders. None of the mortality CpGs overlapped with previously identified 
age-related CpGs, but many of them were differentially methylated in smokers. Recently, 
more EWAS publications reported CpGs associated with all-cause mortality [92,93]. 
However, CpGs reported from these publications poorly replicated each other. Moreover, 
other than methylation level, methylation variability and epigenetic mutation may also predict 
mortality as they are biomarkers of aging.  
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2 AIMS  
 
In Study I, we aimed to identify age-related CpGs from a longitudinal EWAS on age. We 
also aimed to investigate genetic and environmental effect on age-related CpGs from the 
analysis on twins and meQTLs. 
In Study II, we aimed to develop a method that could properly model the longitudinal change 
of DNA methylation variability with age, and to apply it on longitudinal methylation data to 
identify age-varying CpGs. 
In Study III, we aimed to comprehensively analyze epigenetic mutations in association with 
age and other factors. 
In Study IV, we aimed to explore DNA methylation levels and methylation variability in 
association with all-cause and cause-specific mortality. 
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3 DATA SOURCES 
3.1 STUDY POPULATION 
3.1.1 The Swedish Adoption/Twin Study of Aging (SATSA)  
The Swedish Adoption/Twin Study of Aging (SATSA) [94] is the main study cohort in this 
thesis. It is a cohort of old Swedish twin and aims to study genetic and environmental factors 
that cause individual differences in aging. SATSA was started in 1984 and the participants 
were followed every three years until 2014. Questionnaires and biological samples were 
collected from study participants longitudinally during the follow-ups. In this thesis, we 
measured DNA methylation data using blood samples from 402 participants, including 85 
MZ and 116 DZ twin pairs. In total 1122 samples were measured at five time-points from 
1992 to 2012. After quality control on methylation data, we retained 1011 samples from 385 
participants for statistical analysis. 
The characteristics of SATSA participants who contributed DNA methylation samples are 
shown in Table 1. SATSA participants were old with a mean age of 68.6. There were slightly 
more female participants than male. Some participants died during the follow-up time and 
new participants were recruited. 
The genetic data of SATSA participants were also measured as described in section 3.4. Due 
to the QC on genetic data, in total 994 samples from 375 participants were available for both 
genetic and methylation measures. That resulted in a smaller sample size in Study III 
compared to the rest studies. 
Table 1. The characteristics of SATSA participants whose DNA methylation data were used 
in this thesis.  
Longitudinal  
wave 
Year of sample 
collection 
Number of 
Participants  
(new recruits) 
Female 
Proportion 
Age 
mean (SD) 
1 1992-1994 239 59% 68.6 (9.1) 
2 1999-2001 242 (102) 63% 71.2 (10.1) 
3 2002-2004 188 (26) 54% 72.1 (9.1) 
4 2008-2010 186 (15) 61% 76.2 (8.5) 
5 2010-2012 156 (3) 66% 77.9 (8.4) 
 
3.1.2 External cohorts 
In Study I, two external cohorts were used to independently replicate results of longitudinal 
EWAS on age. In Both cohorts, longitudinal measures of DNA methylation from blood 
samples were available to exam the reproducibility of our results in a longitudinal perspective. 
The study characteristics of both external cohorts are shown in Table 2. Both cohorts measure 
DNA methylation from blood samples using 450k array.  
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The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) [95] study 
included 196 Swedish people. In total 390 samples were collected from participants at age 70 
and 80. Half participants in PIVUS were women.  
The Lothian Birth Cohort (LBC) [96] study includes two birth cohorts, LBC1936 and 
LBC1921 [19]. A total of 1342 Scottish people were involved in the study. Participants of 
both sub-cohorts were measured up to three times. At the baseline, LBC1936 included 906 
participants with a mean age of 69.6 years, and LBC1921 included 436 participants with a 
mean age of 79.1 years. The proportion of women was 49.4% in LBC1936 and 53.7% in 
LBC1921.  
Table 2. Characteristics of the longitudinal DNA methylation samples from PIVUS and LBC. 
Cohort Longitudinal wave Participants Mean age Female proportion 
PIVUS 
1 196 70.0 50% 
2 194 80.0 50% 
LBC1936 
1 906 69.6 49% 
2 801 72.5 48% 
3 619 76.3 48% 
LBC1921 
1 436 79.1 60% 
2 174 86.7 54% 
3 82 90.2 54% 
 
3.2 PHENOTYPIC DATA 
Phenotypic data were also collected from SATSA participants repeatedly during the follow-
up. The phenotypic data used in this thesis included age, sex, twin zygosity and smoking 
status. The age, sex and zygosity information of the participants are described in section 3.1.1. 
The smoking status of participants were collected from questionnaires corresponding to the 
collection of blood sample. For the first available measure of the 385 participants, 304 were 
current-smokers, 15 were ex-smokers and 66 were never-smokers. 
Some additional information was obtained by linking to registry data through personal ID, 
including date of cancer diagnosis, date of all-cause mortality and date of cause-specific 
mortality. The date of cancer diagnosis was retrieved from the National Patient Registry 
updated until May 2016, including ICD-codes for all cancer types (ICD7 codes 140-205, 
ICD8 codes 140-209, ICD9 codes 140-208, ICD10 codes C00-C97 and B21). In SATSA, 29 
participants were diagnosed with cancer before the first observation, and 79 incident cases 
during the follow-up time. 
The date of all-cause mortality were obtained from the Swedish National Register prior to 
May 2018. 236 participants died during the follow-up. The cause-specific mortality were 
obtained from the Cause of Death Registry prior to December 2016. A number of 46, 68, 30 
and 46 participants died from cancer, CVD, stroke and dementia respectively. 
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3.3 DNA METHYLATION DATA  
3.3.1 Microarray data 
The 450k array was used to measure DNA methylation data used in this thesis (described in 
section 1.1.3). The raw methylation data obtained from methylation chip were pre-processed 
before statistical analysis. There are a number of approaches and software packages available 
for data preprocessing [97]. The preprocessing of the 450k array data used in this thesis 
included three steps: 1) quality control (QC), 2) normalization, 3) cell count and batch 
corrections. The preprocessing was implemented in the R package "RnBeads" [98]. 
The first step, QC, aims to remove low-quality samples and probes as they are not reliable. 
Usually, low-quality measurements have insufficient signals due to the lack of input DNA. 
The concept "detection p-value" created by Illumina can determine if a probe signal is 
sufficiently larger than the background noise measured by negative control probes. We 
adopted an algorithm named "greedy-cut" [98] to iteratively remove samples and probes with 
detection p-values over 0.05, optimizing the sensitivity and specificity. Another potential 
quality issue is sample contamination or mix-up. It can be detected by the 65 control probes 
that target SNPs instead of CpGs. We compared genotypes of 15 out of 65 SNPs available 
from a SNP array (described in section 3.4) with results from the QC probes, and calculated a 
correlation for each sample. Samples with a correlation lower than 0.7 were considered to be 
contaminated and were removed. Also, the ratio between probe signals from the X and Y 
chromosomes can be used to predict the sample sex, and we removed samples that were 
predicted to be the opposite sex. Moreover, probes that overlap with SNPs in their sequences 
were removed as they may not well hybridize to target DNA, resulting in unreliable 
measurements. In the end, we removed probes for sex chromosomes as we were not 
interested in them. After QC, we retained 390894 CpGs and 1011 samples for statistical 
analysis.  
The second step of pre-processing was normalization. Raw methylation data need to be 
normalized to ensure that all the measurements follow the same distribution. A number of 
normalization methods are available to control color bias, subtract background signals and 
adjust difference between type I and type II probes [99,100]. In this study, we implemented 
the background correction method "noob" from the R package "methylumi" [101] followed 
by a normalization method names "dasen" from the R package "wateRmelon" [102]. 
The third step included correction for cellular compositions and batch effect. The Houseman 
method [21] was used to predict cellular compositions. The method first identify top cell-
specific CpGs from sorted blood-cell reference samples, and then use them to predict cellular 
compositions of study samples. We used 10 Swedish samples [103] as the reference panel 
and predicted the compositions of 9 blood cell types. Next, we used a simple linear regression 
to regress out the estimated cellular compositions from the normalized methylation data. 
Residuals from the model were transformed back to the scale of methylation data in beta-
values. 
  13 
Batch effect is a well-known type of bias caused by technical difference between experiments. 
Potential batch effect in methylation array can be the mean difference of measurements 
between plates, well positions, date of experiments and so on. We examined the distribution 
of our data and identified slides as the major batch effect. The "ComBat" method [104] 
implemented in the R package "sva" [105] was used to remove the known batch effect.  
In the end, the methylation data were transformed into M-values for statistical analysis. 
3.3.2 Bisulfite pyrosequencing data  
Pyrosequencing is a method of DNA sequencing. Followed by the bisulfite conversion, 
pyrosequencing can also measure DNA methylation level as well. Compared to the 450k 
array, pyrosequencing only targets a specific region, usually a few hundred bps, but is 
capable of measuring the methylation levels of all CpGs within the region. In Study III, we 
used pyrosequencing as an alternative method to verify epigenetic mutations identified from 
the 450k array. 
We selected 93 samples from 26 individuals to measure the methylation levels in four CpGs. 
The four CpGs are cg05270750, cg17338133, cg25351353, cg05124918. They were selected 
because they were frequently mutated in many samples and high-quality primers could be 
designed to cover them. Samples were then selected from participants of five measures to 
ensure at least five mutated samples in each of the four CpGs. 
3.4 GENETIC DATA  
The genetic data of SATSA participants were first directly genotyped using the Illumina 
PsychChip, which detected 588,454 SNPs for each individual. The QC on genetic data 
removed samples of high missing call rate, wrong relatedness between individuals and 
wrongly predicted sex, as well as SNPs of high missing call rate, not mapping to a 
chromosome and without minor allele. 
After QC, the genetic data were imputed to predict unmeasured SNPs. Following a pre-
phasing step, the genotyped data were imputed using IMPUTE2 with default parameters 
[106]. The imputation used the 1000 Genomes Project phase 1 [107] as the reference. Next, 
another QC on the imputed data removed SNPs of low quality (Info<0.6) and low minor 
allele frequency (MAF<0.05). Finally, the genetic data used in this thesis included 363 
participants and over 6.5 million SNPs.  
3.5 GENE EXPRESSION AND DNA METHYLATION IN CANCERS 
In Study III, external RNA sequencing data of gene PRDM7 were downloaded from The 
Cancer Genome Atlas Program (TCGA) through Wanderer [108]. The gene encodes a 
histone-lysine trimethyltransferase and was selected as it was related to a CpG (cg05270750) 
validated by pyrosequencing. We targeted the four most common types of cancer in human: 
lung cancer, breast cancer, colorectal cancer and prostate cancer. The specific cancer types 
available in TCGA were lung squamous cell carcinoma, lung adenocarcinoma, breast 
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invasive carcinoma, colon adenocarcinoma and prostate adenocarcinoma. For each cancer 
type, the gene expression were measured from both tumor and normal adjacent tissues. The 
sample size of all cancer types combined was 2209 for tumor tissue and 261 for normal 
adjacent tissue.  
The corresponding DNA methylation data were also downloaded for these cancer types. 
There were 16 CpGs related to gene PRDM7 available in TCGA, of which 15 CpGs were 
available in our methylation data. 
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4 METHODS 
4.1 STATISTICAL METHODS  
4.1.1 Modeling longitudinal data 
Mixed effect model is a popular method to model longitudinal and related samples. In a 
mixed effect model, the effect of clustered groups, such as repeated measurements from the 
same individual, are adjusted as random effects by assuming samples from each group follow 
a normal distribution. Mixed effect model was widely applied in the first three studies of this 
thesis.  
In Study I, we used a mixed effect model to regress DNA methylation levels on age. Sex was 
adjusted as a fixed effect. The longitudinal measures and twin pairs were adjusted as two 
random effects of random intercept, where the former is nested in the latter effect. It is also 
reasonable to assume that the rates of age-related change in methylation levels are different in 
people. However, adding a random slope in the model did not contribute much, but greatly 
increased the computational complexity in an EWAS study of half million regressions.  
In Study II, we used a two-step approach including a linear model and a mixed effect model 
to measure the longitudinal change of inter-individual methylation variability, as an extension 
of Breusch–Pagan test [109] in longitudinal data. The method was tested in simulated data as 
described in section 4.1.3. In the first step, a linear model was used to regress methylation 
levels on age, and then a mixed effect model of random intercept was used to regress the 
absolute residuals from the first step on age. The simulated data proved that this method 
could properly measure the longitudinal change of variability with good statistical power.  
In Study III, we used a mixed effect model to regress the longitudinal change of the number 
of epigenetic mutations with age. The outcome variable, the number of epigenetic mutations, 
was log-transformed so the distribution was close to normal. The fixed effects in the model 
included age, sex, B cell proportion, sample quality and the first genetic PC. Twin pairs and 
batch effect were adjusted as random effects. The repeated measures were not adjusted as it 
was nested in twin pairs and almost did not change the result. Although the batch effect was 
adjusted in QC, it was again adjusted as a random effect in the model because outlier analysis 
is sensitive to technical factors.  
4.1.2 Identification of cis-meQTLs 
The associations between genotypes and DNA methylation was studied and reported in Study 
I. In total 6.5 million imputed SNPs and CpGs were used in the test. To reduce the calculation 
complexity, we only identified cis-meQTLs, which means the associated SNP and CpG were 
located within 1 million bps. A linear model was used to regress methylation level on 
genotype adjusting for age, sex and the first four genetic PCs as covariates.  
The identification of cis-meQTLs was implemented in two steps. First, the R package 
"MatrixEQTL" [110] was used to efficiently identify cis-SNP-CpG associations and calculate 
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a total of 1.94×109 tests. Next, the 2.5×106 associations with p<1×10-5 were again tested in a 
linear model in combination with the robust standard error to adjust for sample correlation. 
4.1.3 Data simulation and model evaluation 
Simulated data were generated in Study II to evaluate the performance of methods for 
describing the longitudinal change of variability. The data simulated the longitudinal change 
of methylation levels with age in 30 subjects. The baseline ages of subjects were generated 
from a normal distribution. Subjects were measured in five waves for every 5 years. The 
baseline methylation levels were generated from a normal distribution. The individual rate of 
the change in methylation level with age was positively correlated with the intercept. In short, 
the simulation was based on a random intercept and slope model, where the intercept and 
slope were correlated. Therefore, the variability of methylation levels increased with age at a 
constant rate. In order to statistically compare model behavior, data were simulated 100 times 
with the same parameters but different random number generators for each test.  
After selecting the optimal method, we changed the parameters of data simulation to test the 
model behavior under different circumstances, including the length of follow-up intervals, 
numbers of follow-ups and the number of subjects. The distributions of estimates and t-
statistics from the method showed how these factors influenced the model results. 
4.1.4 Identification of epigenetic mutations  
In Study III, the term epigenetic mutations were used to describe outlier samples in the 
distribution of DNA methylation. The definition of being an outlier followed a previous 
publication [57], which is three times interquartile range (IQR) lower than the first quartile or 
higher than the third quartile (Figure 4). For each CpG, we identified outliers as epigenetic 
mutations from the distribution of beta-values. Then we counted the total number of 
epigenetic mutations in samples, which was the primary outcome variable in the study. 
Age and sex are the two major factors in DNA methylation. The identification of epigenetic 
mutations was stratified by sex to avoid the misclassification of outliers due to sex difference. 
On the other hand, from the longitudinal data, only the first available measure of each 
individual were used to identify epigenetic mutations. There were two reasons to use the first 
observation without stratification by age: 1) It provided a distribution of independent samples 
with a maximized sample size; 2) The samples of the first observation were relatively young, 
so they provided a methylation distribution of relatively normal and healthy samples. This 
was consistent with the study hypothesis that epigenetic mutations were developed and 
accumulated in the aging process. 
As the methylation level of some CpGs are highly influenced by genetics, the outliers in these 
CpGs may simply have a different genotype, rather than being caused by biological factor 
related to aging. Thus, we excluded CpGs related to cis-meQTL (described in section 4.1.2) 
from counting the number of epigenetic mutations in samples.  
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Methylation outliers can have two directions in different CpGs, either higher or lower than 
average methylation levels. The term highly methylated outlier (HMO) was used to describe 
outlier samples that had methylation levels much higher than the majority, and the term lowly 
methylated outlier (LMO) for the opposite cases (Figure 4).   
 
Figure 4. The distribution of A) cg02018277 and B) cg15057747 are examples of epigenetic 
mutaions in two directions. 
The number of outlier samples in CpGs has a skewed distribution, where most CpGs have a 
small number of outliers. However, some CpGs were more vulnerable to epigenetic 
mutations and thus their properties were interesting (Figure 5). To specifically study them, 
CpGs of more than 50 outlier samples were called frequently mutated CpGs. Then, the 
number of frequently mutated CpGs, and in combination with HMO/LMO, were calculated 
for each sample. 
 
Figure 5. The distribution of the number of oulier samples in CpGs, stratified by high 
methylation outliers (HMOs) and low methylation outliers (LMOs).  
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4.1.5 Survival analysis  
In Study III, the Cox proportional hazard (Cox) model was used to estimate the effect of 
epigenetic mutations on cancer diagnosis. The longitudinal number of epigenetic mutations 
was used as a time-varying covariate. Attained age was adjusted as the underlying time scale. 
Sex and baseline smoking status were adjusted as covariates. Both twin pair and batch effect 
were adjusted by robust standard error.  
In Study IV, the Cox model was used to analyzed methylation levels and methylation 
variability in association with all-cause and cause-specific mortality respectively. Attained 
age was adjusted as the time scale. Sex and smoking status were adjusted as covariates. Twin 
pairs were adjusted by robust standard error. To apply the Cox model on longitudinal 
measures, DNA methylation was modeled as a time-varying covariate. For each event, the 
most recent measurements of all available participants contributed to the prediction. An 
alternative way of modeling longitudinal exposure on time-to-event outcome is the joint 
model, which is a combination of a mixed effect model that models the longitudinal exposure, 
and a survival model that uses estimated exposure from the mixed model to predict the 
outcome. Theoretically, the joint model is the better choice to model the longitudinal 
methylation effect on mortality, as it makes use of longitudinal information of DNA 
methylation. However, in practice, the joint model was much more complicated and slower 
than the Cox model, making it inappropriate for an EWAS of half-million tests.  
In Study IV, we also tested the time-varying effect of methylation on all-cause mortality. We 
added a covariate of age-methylation interaction to model a linear change of methylation 
effect over age. The age in the interaction covariate was centered at age 70, so that the 
estimate from the methylation represented the effect at age 70. 
4.2 REGULATORY FEATURES 
To interpret biological functions of significant CpGs identified from EWAS, we annotated 
regulatory features of target CpGs to explore their roles in gene regulation. In this thesis, the 
genome annotation of regulatory features was sourced from the Ensembl Regulatory Build 
[111]. Genomic regions involved in gene regulation are classified into Promoters, Promoter 
flanking regions, Enhancers, CTCF binding sites, Transcription factor binding sites and Open 
chromatin regions. The classification was based on experimental data from open chromatin 
assays, histone modification assays and transcription factor binding assays. These 
experimental data provided patterns of chromosome availability and epigenetic modifications, 
which were used to predict cell-type specific chromatin states. States from all available cell 
types were then combined to predict regulatory features [112] (Figure 6).  
In practice, to annotate the regulatory feature of a CpG, we created a 50bps slice that covered 
the target CpG in the center and searched for regulatory regions overlapping with the slice. 
To ensure reproducibility, we used the regulatory build released in November 11th, 2016.  
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Figure 6. The process of predicting regulatory features from experimental data. The figure is 
modified from Ernst et al. [112] with permission from Springer Nature. 
4.3 FUNCTIONAL ANNOTATION  
To explore the function identified CpGs and their related genes, we used the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) online tool [113,114] to 
annotate the gene ontology terms in this thesis. The related gene of a target CpG is available 
from the 450k manifest file. The DAVID tool can take a list of genes with a background 
reference to look for enrichment in cellular functions, pathways and disease associations. The 
enrichment was calculated based on the co-occurrence with genes in functional categories. 
The gene ontology terms was reported in this thesis to describe the attribute and potential 
functions of the interesting genes.  
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5 RESULTS AND INTERPRETATION 
5.1 STUDY I - DNA METHYLATION LEVELS CHANGE WITH AGE 
5.1.1 Longitudinal EWAS on age 
From the longitudinal EWAS on age, we identified 1316 CpGs of which the methylation 
levels were significantly associated with age under Bonferroni correction (p<1.3×10-7). The 
methylation level of the top finding cg16867657, which locates in the promoter region of the 
gene ELOVL2, longitudinally increased with age (p=2.3×10-31). The strong age association of 
cg16867657 has been reported before [70] and was later verified in vitro [115].  
Our results were overall consistent with the previous cross-sectional studies using 450k data 
(Table 3). The number of significant results from studies varied largely from hundreds to ten 
thousands, due to different study designs and choices of threshold. Our finding were mostly 
covered by studies which reported a large number significant CpGs, especially in Johansson, 
2013 [68] that also used Swedish data.  
The age-associated CpGs were further validated in two external cohorts with longitudinal 
measures of DNA methylation (described in section 3.1.2). Under a Bonferroni-correction 
threshold, more than half of our results were verified in LBC but only less than 10% were 
verified in PIVUS. The correlation of effect sizes was 0.87 between SATSA and LBC, and 
0.57 between SATSA and PIVUS. The difference in replication performance was possibly 
because study characteristics of SATSA was more similar to LBC than PIVUS. Compared to 
PIVUS, LBC had a larger sample size, wider age range, longer follow-up time and more 
replicated measures.  
Table 3. Summary of age-related CpGs identified in SATSA and in previous publications. 
Study 
Significant 
CpGs 
Analyzed in 
PIVUS/LBC 
Validated in 
PIVUS/LBC 
Study type 
SATSA 1316 - - Longitudinal 
PIVUS - 1271 118 Longitudinal 
LBC - 973 594 Longitudinal 
 
 Analyzed in 
SATSA 
Validated in 
SATSA 
 
Florath, 2013 [69] 162 153 81 Cross-sectional 
Johansson, 2013 [68] 137,993 116,042 1,192 Cross-sectional 
Dongen, 2016 [31] 135,775 117,406 873 Cross-sectional 
Tan, 2016 [116] 2,284 2,087 302 Longitudinal 
Horvath, 2013 [73] 353 316 15 Epigenetic-clock 
Hannum, 2013 [66] 71 63 33 Epigenetic-clock 
 
Age-associated CpGs identified in this study were more located in CpG shores and less in 
CpG islands and open sea regions, compared to all CpGs after QC. Most hypermethylated 
CpGs (85.2%) were located in CpG islands (Figure 7A). The annotation of regulatory 
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features showed that age-associated CpGs were enriched in CTCF binding sites, promoter 
flanking regions and other transcription factor binding sites (Figure 7B). Different to previous 
beliefs, age-related hypermethylated CpGs were not strongly enriched in promoter regions. 
Instead, they were more located in TF binding sites without known regulatory features. The 
enhancers and open chromatin regions were poorly covered by the 450k array. 
We further mapped the age-associated CpGs to 878 genes and annotated their gene functions. 
Seven enriched GO terms were identified under FDR<0.05. The top functions included 
homophilic cell adhesion via plasma membrane adhesion molecules, nervous system 
development and neurogenesis. Thus, genes regulated by age-associated CpGs could have 
important functions in inflammatory response and nervous system.  
 
Figure 7. The distributions of age-associated and background CpGs in A) CpG islands and B) 
regulatory features.  
5.1.2 Genetic and age effect on DNA methylation  
Our study on cis-meQTLs reported over 1.4 million significant associations under Bonferroni 
correction (p<2.5×10-11). Stronger associations were observed when the associated SNP and 
CpG were closer each other (Figure 8). In total 14,714 CpGs were significantly associated 
with at least one SNP, suggesting around 3.7% CpGs from 450k array are highly influenced 
 22 
by genetic. Our results were in general consistent with mQTL database [32], a previously 
published study on meQTLs. About 44% of our identified SNP-CpG associations were 
validated (p<10-14) in the middle-age group from the mQTL database. 
 
Figure 8. The p-values of associations between CpGs and cis-SNPs in relation to their 
distances in the genome. More associations (blue) and lower p-values were observed when 
associated SNP-CpG pairs are closer. 
We further studied how age and genetic effects on DNA methylation interplay. Of the 1316 
age-associated CpGs, 123 (9.3%) were associated with at least one SNP, which was higher 
than the proportion of SNP-associated CpGs in all CpGs (3.7%; p=6.7×10-26). We further 
included related SNPs in the GWAS model of these CpGs. The age effects mostly stayed 
unchanged and no interaction was observed between age and SNPs. 
We also used the twin design to study genetic and age effects. We calculated standardized 
Euclidean distances of DNA methylation between paired twins measured at the same time, 
and regress the distance on age, sex and zygosity. Taking all CpGs into account, the 
methylation difference between twins increased significantly with age (β=0.021, p=9.4×10-4, 
Figure 9A). The age effect was stronger by calculating the distance of 1316 age-associated 
CpGs (β=0.029, p=2.9×10-5; Figure 9B). For SNP-associated CpGs, the age effect was 
smaller but still statistical significant (β=0.015, p=3.32×10-5; Figure 9C). Therefore, age-
associated CpGs could have higher age-induced variations as well, implying that they are 
more influenced by environmental and stochastic effects. 
On average, the methylation difference between DZ paired twins was 5.2% higher than that 
of MZ paired twins using all CpGs. This number was 9.8% for age-associated CpGs and 42.8% 
for SNP/associated CpGs. We did not detect an age-zygosity interaction. Overall, results from 
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the twin analysis agreed with results from meQTL, as both suggested stronger genetic effect 
on age-related CpGs than average.  
 
Figure 9. The methylation differences between paired twins in association with age and 
zygosity in SATSA. Methylation differences were calculated from Euclidean distances of A) 
all CpGs, B) age-associated CpGs, and C) SNP-associated CpGs.  
5.2 STUDY II - DNA METHYLATION VARIABILITY INCREASES WITH AGE  
5.2.1 Method development  
We performed a simulation study to determine an appropriate method based on the Breusch–
Pagan test [109] to estimate the inter-individual methylation variability in longitudinal data. 
The generation of the simulated data is described in section 4.1.3. The Breusch–Pagan test 
includes two steps of regression: first regress out the independent variable, and then model 
the absolute residuals from the first step on the independent variable to estimate the change of 
variance.  
For the first step, we tested a simple linear model (Model 1.1, Figure 10A), a random 
intercept and slope model (Model 1.2, Figure 10E), and a random intercept model (Model 1.3, 
Figure 10G). Only residuals from Model 1.1 captured inter-individual variability as the 
absolute residual increased with age. In the second step, we tested the same three models to 
regress the absolute residuals on age (Figure 10B-D). Model 2.3 was chosen as it had the best 
statistical power which is important in EWAS. Therefore, we concluded that a linear 
regression followed by a random intercept model could properly measure the longitudinal 
change of inter-individual variability over time.  
We also tested the model performance under different circumstances. We simulated datasets 
of different age ranges and follow-up intervals. The estimated age effect on variability stayed 
unchanged, but the longer follow-up time provided better statistical power. We also tested the 
model with different numbers of participants and repeated measures. Again, the estimated age 
effect stayed unchanged, but both the number of participants and the number of measures 
were positively associated with the test power. 
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Figure 10. Models tested on simulated data to determine an appropriate method for testing 
heteroscedasticity in longitudinal data. A) The simple linear model (Model 1.1) generated 
absolute residuals that measured inter-individual variability. The absolute residuals were then 
regressed on age by B) a simple linear regression (Model 2.1), C) a random intercept and 
slope model (Model 2.2) and D) a random intercept model (Model 2.3). E) The random 
intercept and slope model (Model 1.2) best fitted the simulated data. F) But the absolute 
residuals captured intra-individual variability. G) The random intercept model (Model 1.3) 
was also tested. H) But absolute residuals were not associated with the age. 
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5.2.2 Longitudinal EWAS of methylation variability and age  
After determining the proper method, we applied the method in an EWAS to estimate the 
change of inter-individual variability of DNA methylation with age. The results showed that 
90.4% of all CpGs had positive effect sizes, indicating the variability of most CpGs increased 
with age. We identified 570 significant age-varying CpGs after Bonferroni correction 
(p<1.3×10-7). These age-varying CpGs were mapped to 246 genes and the functional analysis 
of those genes in DAVID online tool [113] showed them enriched in the GO term “nervous 
system development” (p=1.9×10-5, FDR=0.034).  Our study results were consistent with a 
previous cross-sectional study [87], which replicated 218 of the 570 CpGs identified in our 
study. Their functional analysis also reported enriched gene function in neuron development. 
Considering the smaller sample size (1011 samples from 385 individuals versus 3295 
samples) and narrower age range (48 to 99 year versus 10 to 90 year) in our study, the high 
replication rate suggests that our method was correct and robust.  
We further compared them with the age-associated CpGs reported in Study I, and found 7 
CpGs to be both age-associated and age-varying (Figure 11A and B). We also found 14 age-
varying CpGs associated with genetic variants, including one (cg06464078) of which the 
methylation variability decreased with age (Figure 11D). Basically, the average methylation 
levels of most age-varying CpGs stayed unchanged with age, which is similar to the previous 
study [87]. This implies that age-related and age-varying CpGs may have different 
mechanisms in aging.  
 
Figure 11. Examples of longitudinal change of DNA variability with age. A) The methylation 
levels of cg21585707 decreased with age but the variability increased with age. B) Both 
methylation level and methylation variability of cg05666820 increased with age. C) The 
methylation variability of cg03689146 increased with age but the average methylation level 
stayed unchanged. D) The methylation variability of cg06464078 decreased with age, and 
was also associated with a SNP rs34800081. 
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5.3 STUDY III – EPIGENETIC MUTATIONS INCREASE WITH AGE 
5.3.1 Epigenetic mutation in association with age and other factors 
Epigenetic mutations were identified and counted in SATSA as described in section 4.1.4. 
We verified the cross-sectional finding that the number of epigenetic mutations exponentially 
increased with age (p=1.22×10-13) in longitudinally data. Additionally, we found other factors 
associated with the number of epigenetic mutations (Table 4), including female (p=6.33×10-3), 
low sample quality (p=1.48×10-117), CD19+ B cell composition (p=5.06×10-23), cancer 
diagnosis (p=0.014) and the first genetic PC (p=0.041). 
As epigenetic mutations are outliers, they were expected to be strongly affected by technical 
factors including sample quality and batch effect. Although low-quality measurements were 
largely removed in QC, sample quality still plays a major role in the number of epigenetic 
mutations. The same applies to the batch effect so we additionally adjusted batch as a random 
effect. As a result of sample randomization on the 450k array, technical factors did not 
confound the age effect on epigenetic mutations in this study. However, for a single CpG, it is 
difficult to distinguish outliers induced by technical factors from that caused by biological 
factors. The strong effect of CD19+ B cell on epigenetic mutations could be explain by the 
unique methylation pattern of B cell compared to other lymphocytes [103]. The minor genetic 
factor could be caused by CpGs associated with trans-meQTLs which were not removed. 
We further classified them into HMOs, LMOS and frequently mutated CpGs as described in 
section 4.1.4. We have found 1,185 (0.32%) frequently mutated CpGs, and two of them were 
associated with age identified in Study I. The number of frequently mutated CpGs were also 
significantly associated with age, sample quality, CD19+ B cell compositions, cancer 
diagnosis and  genetic PC1, but not with sex (Table 4). 
More HMOs were found in frequently mutated CpGs than LMOs (969 and 216, p<1×10-16, 
Figure 5), which is consistent with a previous publication [117]. We further studied frequent 
HMOs and frequent LMOs, and found stronger effects of age, B cell, genetic PC1 on the 
former (Table 4). However, frequent LMOs were much more affected by sample quality than 
frequent HMOs (Table 4). 
The different effect of covariates on frequent HMOs and LMOs suggested that the direction 
of epigenetic mutation was important. Frequent HMOs were more associated with biological 
factor like age and B cells. On the other hand, the number of frequent LMOs was small but 
more affected by sample quality, making it difficult to study their biological functions. 
Moreover, a survival analysis of epigenetic mutations in association with cancer diagnosis 
showed that a higher number of frequent HMOs could be a risk factor (p=0.048). However, 
the total epigenetic mutations and frequent LMOs were not associated with cancer diagnosis. 
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Table 4. The longitudinal associations between number of epigenetic mutations (log10-
transformed) and age and other covariates. 
 Effect sizes; ( p-values ) 
Number of 
epigenetic 
mutations 
Age 
(year) 
Sex (Female 
to male) 
CD19+ B 
cells 
(proportion) 
1st genetic 
principal 
component 
Sample 
quality 
Cancer 
diagnosis 
Total 
epigenetic 
mutations 
8.29e-03 
(1.22e-13) 
0.0722 
(6.33e-03) 
4.21 
(5.06e-23) 
0.445 
(0.0413) 
0.369 
(1.48e-117) 
0.0697 
(0.0139) 
Frequent 
epigenetic 
mutations 
6.03e-03 
(2.17e-19) 
-0.0180 
(0.33) 
1.76 
(1.37e-12) 
0.595 
(1.28e-04) 
0.0573 
(5.84e-13) 
0.0478 
(0.0164) 
Frequent high 
methylation 
outliers 
6.81e-03 
(2.09e-17) 
-0.0314 
(0.16) 
2.09 
(2.25e-12) 
0.750 
(7.65e-05) 
0.0512 
(3.58e-08) 
0.0602 
(0.0130) 
Frequent low 
methylation 
outliers 
2.82e-03 
(1.14e-05) 
0.0340 
(0.057) 
0.474 
(0.046) 
0.0186 
(0.92) 
0.0888 
(8.09e-30) 
-6.99e-03 
(0.71) 
 
To study epigenetic mutations in relation to cancer, we analyzed DNA methylation data of 
gene PRDM7 downloaded from TCGA. Methylation levels of the gene body were much 
higher in tumor tissues than normal adjacent tissues, but no significant difference in the 
promoter. Therefore, tumor tissues were observed to have more epigenetic mutations in gene 
body but not in the promoter. As the normal adjacent tissue is between the normal and tumor 
tissue, the result suggested that epigenetic mutations may first appear in the promoter in 
cancer development. 
5.3.2 Validation in bisulfite pyrosequencing 
As the identified epigenetic mutations could be technical artifacts, we selected one HMO and 
three LMOs to validate in bisulfite pyrosequencing (described in section 3.3.2). The 
pyrosequencing results and the corresponding 450k data are presented in Figure 12. In 
general, methylation levels measure from pyrosequencing were well correlated with that from 
the 450k array (cg05270750: r=0.84; cg17338133: r=0.59; cg25351353: r=0.80; cg05124918: 
r=0.77). Also, pyrosequencing results showed that epigenetic mutations identified from 450k 
array were significantly different to normal samples. Therefore, epigenetic mutations 
identified from the 450k array were successfully validated.  
But still, we observed disagreement between pyrosequencing and 450k data in some samples, 
where four samples in cg17338133 and six samples in cg05124918 showed over 15% 
difference in methylation level between the two methods. It might indicate that we wrongly 
detected or failed to detect epigenetic mutations from 450k chip data. In general, changes in 
methylation levels from pyrosequencing were smoother than that from 450k array (Figure 5). 
Unlike 450k data, we did not observe the recovery of mutated state back to normal during 
follow-ups in pyrosequencing. So we suggested that bisulfite pyrosequencing could better 
present that epigenetic mutations were persistent with and could therefore accumulate in the 
aging process.   
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Figure 12. The longitudinal change of four CpGs in 26 individuals measured by 450k array 
(left panel) and bisulfite pyrosequencing (right panel). Methylation levels of A) cg05270750 
from 450k-chip, B) cg05270750 from Pyroseq, C) cg17338133 from 450k-chip, D) 
cg17338133 from Pyroseq, E) cg25351353 from 450k-chip, F) cg25351353 from Pyroseq, G) 
cg05124918 from 450-chip, H) cg05124918 from Pyroseq. Epigenetic mutations identified 
from 450k array were in red and the reference in blue. 
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5.4 STUDY IV – DNA METHYLATION AND MORTALITY 
5.4.1 EWAS on all-cause and cause-specific mortality  
The EWAS on all-cause mortality in SATSA did not identify genome-wide significant 
association under Bonferroni or FDR correction. Comparing to the three previous 
publications of EWAS on all-cause mortality, we replicated 9/58 [118], 135/2806 [92] and 
42/2552 [93] CpGs with p<0.05 and consistent effect direction respectively.  
To explain the inconsistent results between publications, we tested the potential age-varying 
effect in EWAS. There we identified 6 CpGs with significant age-varying effect on all-cause 
mortality under Bonferroni correction and 193 CpGs under FDR correction. Of the 193 CpGs, 
two were identified as age-related CpG in Study I. A number of 13, 231 and 214 CpGs 
reported from the previous publications [92,93,118] showed age-varying effect under p<0.05. 
Moreover, we observed the effect of methylation level decreased with age, and eventually 
changed to the other direction for all CpGs with the age-varying effect. Such change in 
direction resulted in an average effect close to 0. Two examples of age-varying effect on all-
cause mortality are shown in Figure 13. 
 
Figure 13. Two examples of age-varying effect of DNA methylation on all-cause mortality. A) 
cg00408876 (p=4.35×10-10); B) cg13398947 (p=7.67×10-08). Schoenfeld residual plots were 
used to present the non-proportional hazzard ratio over age.  
The age-varying effect identified from this study could partly explain the low replication rate 
between EWAS on all-cause mortality. Without considering the age-varying effect, different 
studies estimated an average effect of methylation over different ranges of age. This is 
supported by the results that previously reported CpGs were more found to have age-varying 
effect than being replicated in the EWAS without age-varying effect. Moreover, the direction 
of age-varying effect may partly explain that no significant result was identified from the 
EWAS without age-varying effect. 
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In the EWAS on cause-specific mortality, we identified 35 CpGs significantly associated 
with death from cancer under FDR<0.05, but no significant result for death from CVD, stroke 
or dementia. Genes related to those CpGs showed functions strongly related to cancer, such 
as genes coding histone methyltransferase, double-strand break repair protein and Insulin like 
growth factor binding protein. The top 10 CpGs and their gene functions are illustrated in 
Table 5.  
The EWAS results of death from cancer were convincing because their related genes had 
critical functions in cancer biology. But further evidence is needed to explain their biological 
mechanisms in relation to cancer mortality. CpGs related to cause-specific mortality may 
overlap with those related to all-cause mortality, as former outcome is a part of the latter. In 
this study, cancer-mortality CpGs were related to all-cause mortality to some extent, as 20 of 
the 35 CpGs showed a p-value lower than 0.05 in the EWAS of all-cause mortality. However, 
none of them was reported previously [92,93,118].   
Table 5. The first 10 significant results from EWAS on death from cancer and their gene 
functions in relation to cancer. 
CpG  HR* p-value Gene name Gene function related to cancer  
cg03217966 1.74 1.66e-08 EHMT2 Migratory ability of breast cancer [119] 
cg19211619 0.56 4.31e-08 CAPS RNA expression as prognostic marker in 
endometrial cancer  
cg07380540 0.45 4.87e-08   
cg11136886 0.53 1.79e-07   
cg11919479 0.60 3.42e-07 PAFAH1B3 Critical driver of breast cancer pathogenicity [120] 
cg26387956 1.56 4.33e-07 INO80 Oncogenic transcription and tumor growth in non-
small cell lung cancer [121] 
cg17516160 1.87 4.57e-07 MRE11A Code double-strand break repair protein 
cg19942305 1.69 5.13e-07   
cg24901098 1.77 8.25e-07 IGFBP3 Code insulin like growth factor binding protein 
cg06652392 1.79 8.37e-07   
 
5.4.2 Methylation variability in association with all-cause mortality  
Apart from methylation level, we conducted an EWAS to test the methylation variability in 
associated with all-cause mortality (described in section 4.1.5). We identified 2 significant 
CpGs under Bonferroni correction and 29 CpGs under FDR correction (Figure 14A). The top 
CpG is presented in Figure 14B to illustrate the association between methylation variability 
and mortality risk. The Schoenfeld residual test suggested no violation of proportional hazard 
assumption among the significant CpGs. Almost all the CpGs with p<1×10-4 had a positive 
effect size (Figure 14A), which means that people deviate from average methylation levels 
have a higher mortality risk. One of the 29 CpGs was associated with age as reported in 
Study I, but none was among the age-varying CpGs reported in Study II. 
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This study first provided EWAS evidence that methylation variability can be associated with 
all-cause mortality. Although the positive effect direction was expected, it is not clear how 
methylation levels of both directions increase mortality. Also, we found age-varying CpGs 
were not associated with mortality, because the age effect was removed as the time scale in 
the survival analysis, which reduced the effect of factors strongly correlated with age. 
We also tested the number of epigenetic mutations in association with all-cause mortality, but 
did not observe significant association. Although epigenetic mutations can be important to 
aging, they did not have strong enough effect on all-cause mortality for us to detect.   
 
 
Figure 14. Results from the analysis on methylation variability and all-cause mortality. A) A 
volcano plot illustrates that most of the CpGs with p<1×10-4 had a positive effect size as 
colored in red. B) The methylation level of cg27237537, where the variability was associated 
with all-cause mortality.  
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6 GENERAL DISCUSSION AND FUTURE PERSPECTIVE 
Longitudinal studies can provides a higher level of evidence than cross-sectional studies, and 
can sometimes imply causation. Repeated measures are particularly important to study DNA 
methylation as it is dynamic and can be influenced by many factors. Currently, longitudinal 
studies on DNA methylation are still limited as they are high-cost and time-consuming. The 
number of repeated measures and the follow-up time are two key factors in longitudinal study, 
as they make a longitudinal study different to a cross-sectional one. A large number of 
repeated measurements allowed us to test more hypothesis by modeling complicated changes 
of DNA methylation over time, such as a quadratic or breakpoint model. Moreover, twins are 
study subjects matched by nature. By comparing the difference between twins, we can avoid 
many genetic and environmental confounders. Further studies on discordant twins could help 
identify factors associated with age-related diseases.  
Cellular heterogeneity is one of the major confounder in studies on DNA methylation. Recent 
evidences suggested that many EWAS signals would be eliminated after properly adjusting 
for cellular compositions [122]. In most studies, cellular compositions were not measured, but 
estimated based on methylation data. The quality of methylation data, choice of reference and 
algorithms can all affect the estimation. Even cell types are properly estimated and adjusted, 
there are still subtype differences between cells. Future studies on DNA methylation may 
focus on individual cells, particular for studies on cancer.  
Blood samples are the most widely used source of DNA methylation as they are easily 
available. But some methylation signals may only exist in other tissues and are therefore 
missing from studies of blood samples. Brain samples are particularly valuable for studies on 
brain aging and dementia. Also, our study of blood samples identified aging signals related to 
nervous system. However, since brain samples are mostly donated from deceased people, 
DNA started to breakdown after death making it hard to measure DNA methylation.  
Similarly, genetic has a strong effect on DNA methylation and DNA methylation may 
mediate the genetic effect on traits. However, the microarray technique cannot properly 
measure CpGs that are too close to a SNP, or the CpGs themselves are SNPs. Most studies 
simply removed these CpGs as a standard QC procedure. Moreover, rare genetic variants 
may have stronger effect on DNA methylation but are often ignored. Therefore, the genetic 
effect on DNA methylation is underestimated. Future studies using whole-genome bisulfite 
sequencing can better measure the genetic effect on DNA methylation.  
DNA methylation can be affected by so many factors that we probability cannot properly 
adjust all confounders. For GWAS, the Q-Q plot is a powerful method to diagnose unadjusted 
confounders by testing how p-values deviate from a uniform distribution. However, the tests 
in EWAS are not independent so that we expect to see an early deviation in the QQ plot when 
modeling strong factors like age. Further studies are needed to have a better understanding of 
the correlation structure between CpGs and provide a theoretical distribution of test results 
given a hypothesized association.  
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Many CpGs are highly correlated to their neighbors and the alteration of methylation can 
happen at multiple adjacent CpG sites [123]. But still, there is no consensus on local CpG 
regions. In addition, the long-range interaction between CpGs makes it more complex to 
cluster CpGs into groups. The long-range interaction, sometime between chromosomes, is a 
result of physically contact in nucleosome. Thus, studies of chromosome conformation 
capture can help establish the methylation pattern of long-range interactions. 
The regulatory and functional annotations of DNA methylation are essential to understand the 
properties of CpGs identified from EWAS. However, the target genes of regulatory regions 
are still unclear, because CpGs may not regulate the nearest gene, but regulate one or more 
distal genes. This is supported by the fact that CpGs may not correlated with the expression 
of genes close by. Therefore, the better approach is to integrate DNA methylation with other 
epigenetic markers and omics data, in order to determine regulatory functions and study their 
interplays.  
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7 CONCLUSION 
 
In this thesis, we used repeated measures from the SATSA study to investigate mechanisms 
of DNA methylation related to aging from a longitudinal perspective. The mechanisms 
included changes in average methylation level, increase in inter-individual methylation 
variability and increase in the number of epigenetic mutations with age. Further, we analyzed 
these mechanisms in association with all-cause and cause-specific mortality.  
In Study I, we identified age-associated CpGs from a longitudinal EWAS and validated the 
results in external cohorts. The analysis on twins and meQTLs found genetic effect on age-
associated CpGs, but age and genetic effects were independent.  
In Study II, we developed a method to model the longitudinal change of methylation 
variability with age. We then applied the method an EWAS and identified age-varying CpGs 
from longitudinal data. 
In Study III, we verified that the number of epigenetic mutations increased with age in 
longitudinal data, and identified other associated factors. We further validated results using 
bisulfite pyrosequencing and proved that epigenetic mutations were persistent and could 
accumulate with age. 
In Study IV, we observed the age-varying effect of DNA methylation on all-cause mortality, 
which might explain inconsistent results from previous publications. We also identified CpGs 
associated with death from cancer and their gene functions were critical to cancer. 
Furthermore, we provided longitudinal evidence that methylation variability could also 
predict all-cause mortality.  
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